Cellectis and Genoway reach "amicable" resolution to sublicence squabble
This article was originally published in Scrip
Executive Summary
Cellectis and Genoway have settled their legal dispute concerning a non-exclusive sublicence agreement dating back to September 2001 for technology used to develop genetically modified animal models for drug development.